Biotech | January 04, 2022
Yokogawa invests in glycan production company GlyTech
Partnering to build biosynthesis processes and a pharmaceutical production platform
Partnering to build biosynthesis processes and a pharmaceutical production platform
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
The company is marketing the kit under the brand name CoviFind and it can detect the infection in 15 minutes
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
The company has operations in North America, Asia, and Europe,
Acute therapies continue to report strong growth compared to chronic ones.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated
